Does psoriatic arthritis (PsA) alter the risk of cardiovascular morbidity?

Primary tabs

Does psoriatic arthritis (PsA) alter the risk of cardiovascular morbidity?

Many problems are associated with the heart and blood vessel diseases of which many of them are concerned with atherosclerosis. Differentiation between the psoriatic arthritis (PsA) patients with the general population through the observational studies can help to monitor the risk of cardiovascular and cerebrovascular morbidity.

The abstract archives from rheumatology conferences and different databases (Medline, EMBase, and Cochrane) were searched upon efficiently. Based on the following criteria, the observation studies were carried out by the 2 researchers: Comparison group of individuals without psoriasis and rheumatic diseases, PsA diagnosis, cardiovascular or cerebrovascular outcomes and case-control, cross-sectional or cohort studies. Random-effects model and I2 statistic revealed the highest adjusted effect size estimate for cardiovascular and cerebrovascular diseases.

Around 32,973 patients with PsA were a part of the inclusion criteria concerned with the eleven studies. The risk of cardiovascular diseases increased to 43% on distinguishing between PsA with the general population (pooled Odds Ratio (OR) 1.43, 95% Confidence Interval (CI) 1.24, 1.66). Also, there was a growth in the percent of morbidity risks for cerebrovascular diseases, myocardial infarction and heart failure i.e. 22%, 68% and 31% (pooled OR 1.22, 95% CI 1.05-1.41, pooled OR 1.68, 95% CI 1.31-2.15 and pooled OR 1.31 95% CI 1.11, 1.55). All the analyses were notably heterogeneous (P<0.001) concluding overall rise in cardiovascular and cerebrovascular morbidity by 43% and 22% in this comparison study.

Arthritis Care Res (Hoboken).


Log in or register to post comments